# Neoadjuvant chemotherapy or chemoradiation for patients with advanced adenocarcinoma of the oesophagus? A propensity score-matched study.

**Tumor:** Cáncer gástrico/UGE
**Autores:** Favi F
**Revista:** Eur J Surg Oncol (2017)
**PMID:** 28666624 | **PMCID:** —
**DOI:** [10.1016/j.ejso.2017.06.003](https://doi.org/10.1016/j.ejso.2017.06.003)
**Fuente:** PubMed (abstract only)

## Relevancia
Cáncer gástrico/UGE tratado con quimioterapia perioperatoria (FLOT/MAGIC) o inmunoterapia: documenta downstaging ganglionar, valor pronóstico de ypN0 y rendimiento ganglionar tras NAC. Comparable al paradigma mamario: ypN0 tras quimioterapia neoadyuvante es marcador pronóstico fuerte y guía la linfadenectomía D2.

## Abstract
In a propensity-score matched study, we analysed patients with locally advanced AEG type I or II, treated with chemotherapy (FLOT) or chemoradiation (CROSS), followed by oesophagectomy. R0 in 97% CROSS vs 85% FLOT. Major response of primary tumour more often in CROSS (43% vs 27%) and no lymph node metastasis (ypN0 = 68% vs 40%). In multivariate analysis, only ypN-category was an independent prognostic factor. Compared to FLOT, neoadjuvant chemoradiotherapy with CROSS resulted in better response of primary tumour and less lymph node metastasis but without superior survival.

## Acceso
Vía [DOI](https://doi.org/10.1016/j.ejso.2017.06.003) o suscripción institucional.

---
*Datos de PubMed. Citar: doi 10.1016/j.ejso.2017.06.003*
